Prevalence and clinical significance of anti-ribosomal P antibody in childhood-onset systemic lupus erythematosus

Aldar, Henrique; Lapa, Aline Tamires; Bellini, Bruna Siqueira; Sinicato, Nailú Angélica; Postal, Mariana; Fernándes, Paula Teíxeira; Costallat, Lílian Tereza Lavras; Marini, Roberto; Appenzeller, Simone

doi:10.1177/0961203312451201

Cited by 26 publications

(29 citation statements)

References 55 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Agius et al published a case that initially presented with acute psychosis accompanied by chronic movements and of all the lab parameters only ribosomal P antibodies were positive [24]. Moreover in a study by Aldar et al on 50 pediatric SLE patients, antiribosomal P antibodies were positive in 13 patients and only one of these patients had chorea [25]. However, there is no data regarding only antiribosomal P antibodies were positive and antiphospholipid antibodies were negative in this patient.…”

Section: Discussionmentioning

confidence: 92%

A 17-Year-Old Female with Systemic Lupus Presents with Complex Movement Disorder: Possible Relationship with Antiribosomal P Antibodies

Özcan

Altinöz

Karadeli

et al. 2013

Case Reports in Neurological Medicine

View full text Add to dashboard Cite

Complex movement disorder is a relatively rare presentation of neurolupus. Antiphospholipid antibodies are associated with movement disorders likely via aberrant neuronal stimulation. Antiribosomal P antibodies have been previously associated with neuropsychiatric disorders but their correlation with movement disorder was not previously established. Our case report involves a 17-year-old Caucasian female patient positive for only antiribosomal P antibody and lupus anticoagulant who presented with a sudden onset of complex movement disorder. After complete cessation of physical signs with olanzapine, anticardiolipin and anti-β2 glycoprotein I antibodies became positive which indicates a likely discordance between movement disorder and antiphospholipid antibodies. This also indicates a potential causal role of antiribosomal P antibodies in inducing movement disorder.

show abstract

Section: Discussionmentioning

confidence: 92%

A 17-Year-Old Female with Systemic Lupus Presents with Complex Movement Disorder: Possible Relationship with Antiribosomal P Antibodies

Özcan

Altinöz

Karadeli

et al. 2013

Case Reports in Neurological Medicine

View full text Add to dashboard Cite

show abstract

“…Since MDM2 has been demonstrated as an important negative regulator of p53 and anti-p53 was also been reported to be found in SLE patients [ 12 ], whether there was an association between anti-MDM2 and anti-p53 is still unknown. We further investigated the presence of anti-p53 in these SLE patients by ELISA.…”

Section: Resultsmentioning

confidence: 99%

“…In recent years, p53 has been found to be important in both innate and acquired immune regulation [ 20 , 21 ], and it was necessary in the inhibition of autoimmune inflammation [ 22 ]. Several studies have found that the presence of anti-p53 in SLE patient, with a prevalence of about 26%–59%, showed that anti-p53 was related to anti-DNA antibodies and can be used as a marker for detecting the disease activity of SLE [ 12 , 23 , 24 ]. Our study showed that anti-p53 was presented in 39.50% of SLE patients, and the titer of anti-p53 was positively correlated with anti-MDM2.…”

Section: Discussionmentioning

confidence: 99%

Autoantibody to MDM2: A Potential Serological Marker of Systemic Lupus Erythematosus

Liu

Dai

Liu

et al. 2015

Journal of Immunology Research

View full text Add to dashboard Cite

Introduction. Systemic lupus erythematosus (SLE) is one of the systemic autoimmune diseases characterized by the polyclonal autoantibody production. The human homologue of the mouse double minute 2 (MDM2) is well known as the negative regulator of p53. MDM2 has been reported to be overexpressed in SLE animal model and to promote SLE. Since abnormally expressed proteins can induce autoimmune response, anti-MDM2 autoantibody was examined in SLE patients. Methods. Anti-MDM2 antibody in sera from 43 SLE patients and 69 healthy persons was investigated by ELISA. Positive samples were further confirmed by western blotting. The immunological feathers of anti-MDM2 positive sera were analyzed by indirect immunofluorescence assay. Anti-p53 was also investigated in SLE patients by ELISA, and the correlation of anti-MDM2 and anti-p53 was analyzed. Results. The presence of anti-MDM2 in SLE patients was 23.30%, much higher than normal healthy persons (4.30%). These anti-MDM2 positive sera present a nuclear staining pattern. The presence of anti-p53 in SLE patients was 39.50%, and the titer of anti-MDM2 was positively correlated with anti-p53 in SLE patients. Conclusions. Anti-MDM2 autoantibody was detected at high prevalence in SLE patients. The detection of anti-MDM2 in SLE patients should be clinically useful.

show abstract

“…These antibodies can cause apoptosis by increasing the calcium influx and activation of caspase-3 27. For this study, aP-ABs were quantified using a commercial ELISA assay (QuantaLite Ribosome P assay; Kit k981237; Inova Diagnostics; San Diego, California, USA) with values of at least 20 units/mL, representing a positive result.…”

Section: Methodsmentioning

confidence: 99%

Blood-based candidate biomarkers of the presence of neuropsychiatric systemic lupus erythematosus in children

et al. 2014

View full text Add to dashboard Cite

ObjectiveTo examine select brain-reactive proteins for their usefulness to serve as blood-based biomarkers in the screening for neurocognitive deficits in childhood-onset systemic lupus erythematosus (cSLE-NCD).MethodsPatients withcSLE (n=40) were studied longitudinally (month 1; month 18): working memory, psychomotor speed and visuoconstructional ability were assessed using formal neurocognitive testing to determine the presence of cSLE-NCD. Patients also completed the computerised Paediatric Automated Neuropsychological Assessment Metrics. The following brain-reactive proteins were measured in the blood: neutrophil gelatinase associated lipocalin (NGAL), S100B, S100A8/9, antibodies to NR2 glutamate receptor (aNR2-AB), ribosomal-P (aP-AB), glycoprotein-1 (aGP1-AB), and lupus anticoagulant.ResultscSLE-NCD was present in 6 of 40 patients at baseline and 4 of 27 patients with 18-month information. aP-AB positivity was more commonly present with cSLE-NCD than without (p=0.05). aP-ABs were negatively associated with performance on tests assessing working memory, psychomotor speed and visuoconstructional ability in using formal neurocognitive testing. There were also significant negative associations between aP-AB, S100A8/9, aNR2-AB, aGP1-AB, and lupus anticoagulant and accuracy rates on select Paediatric Automated Neuropsychological Assessment Metrics subtests (p<0.05). Over time, decline in cognitive performance was more pronounced among patients with higher NGAL and aNR2-AB levels. Combinations of serum levels of S100A8/9, S100B, NGAL, aNR2-AB and aP-AB were able to identify cSLE-NCD (sensitivity: 100%; specificity 76%) in exploratory analysis.ConclusionsSelect brain-reactive proteins in the blood are associated with cognitive performance and the presence of cSLE-NCD, cross-sectionally and over time. This raises the possibility that testing of these proteins may assist with the screening of cSLE-NCD.

show abstract

Prevalence and clinical significance of anti-ribosomal P antibody in childhood-onset systemic lupus erythematosus

Abstract: Anti-P is frequently observed in cSLE patients and was associated with the presence of anxiety in this cohort of cSLE.

Cited by 26 publications

References 55 publications

A 17-Year-Old Female with Systemic Lupus Presents with Complex Movement Disorder: Possible Relationship with Antiribosomal P Antibodies

A 17-Year-Old Female with Systemic Lupus Presents with Complex Movement Disorder: Possible Relationship with Antiribosomal P Antibodies

Autoantibody to MDM2: A Potential Serological Marker of Systemic Lupus Erythematosus

Blood-based candidate biomarkers of the presence of neuropsychiatric systemic lupus erythematosus in children

Contact Info

Product

Resources

About